Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Eukaryotic Gene Expression
Импакт фактор: 2.156 5-летний Импакт фактор: 2.255 SJR: 0.649 SNIP: 0.599 CiteScore™: 3

ISSN Печать: 1045-4403
ISSN Онлайн: 2162-6502

Выпуски:
Том 30, 2020 Том 29, 2019 Том 28, 2018 Том 27, 2017 Том 26, 2016 Том 25, 2015 Том 24, 2014 Том 23, 2013 Том 22, 2012 Том 21, 2011 Том 20, 2010 Том 19, 2009 Том 18, 2008 Том 17, 2007 Том 16, 2006 Том 15, 2005 Том 14, 2004 Том 13, 2003 Том 12, 2002 Том 11, 2001 Том 10, 2000 Том 9, 1999 Том 8, 1998 Том 7, 1997 Том 6, 1996 Том 5, 1995 Том 4, 1994

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukarGeneExpr.v20.i1.20
pages 17-34

Triple Negative Breast Cancer: From Molecular Portrait to Therapeutic Intervention

Pietro Carotenuto
Pharmacogenomic Laboratory, CROM - Oncological Research Center Mercogliano, 83013 Avellino, Italy
Cristin Roma
Pharmacogenomic Laboratory, CROM - Oncological Research Center Mercogliano, 83013 Avellino, Italy
Anna Maria Rachiglio
Pharmacogenomic Laboratory, CROM - Oncological Research Center Mercogliano, 83013 Avellino, Italy
Gerardo Botti
Surgical Pathology Unit, INT Fondazione "G. Pascale," 80131 Naples, Italy
Amelia D'Alessio
Cell Biology and Biotherapy Unit, INT Fondazione "G. Pascale," 80131 Naples, Italy
Nicola Normanno
Pharmacogenomic Laboratory, CROM - Oncological Research Center Mercogliano, 83013 Avellino, Italy; and Cell Biology and Biotherapy Unit, INT Fondazione "G. Pascale," 80131 Naples, Italy

Краткое описание

Triple negative breast cancer is a subtype of breast cancer that lacks expression of an estrogen receptor (ER), a progesterone receptor (PR), and HER2. It is characterized by its unique molecular profile, aggressive behavior, and distinct pattern of metastasis. Epidemiological studies show a high prevalence of triple negative breast cancer among younger women and those of African descent. Although sensitive to chemotherapy, early relapse is common, and a predilection for visceral metastasis, including brain metastasis, has been described. Gene-expression profiling approaches demonstrated that triple negative breast cancer is a heterogeneous group of diseases composed of different, molecularly distinct subtypes. Although not synonymous, the majority of triple negative breast cancers carry the "basal-like" molecular profile on gene-expression arrays. However, several studies have shown that triple negative breast cancer includes tumors with a non-basal expression profile and, in particular, the "normal-breast," the "multiple marker negative," and the recently identified "claudin-negative" subtypes. Target-based agents, including epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and poly-ADP-ribose polymerase (PARP) inhibitors, are currently in clinical trials and hold promise in the treatment of this aggressive disease.


Articles with similar content:

Molecular Mechanisms Underlying the Role of MicroRNAs in Resistance to Epidermal Growth Factor Receptor-Targeted Agents and Novel Therapeutic Strategies for Treatment of Non-Small-Cell Lung Cancer
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 4
Elena Galvani, Godefridus J. Peters, Mina Maftouh, Elisa Giovannetti, Amir Avan
Glioblastoma Multiforme: The Genetic Perspective of the Treatment Planning
Critical Reviews™ in Eukaryotic Gene Expression, Vol.25, 2015, issue 4
Rasime Kalkan
Review of Triple Negative Breast Cancer and the Impact of Inducible Nitric Oxide Synthase on Tumor Biology and Patient Outcomes
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 5-6
Elaine M. Walsh, Maccon M. Keane, David A. Wink, Grace Callagy, Sharon A. Glynn
Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma
Journal of Environmental Pathology, Toxicology and Oncology, Vol.36, 2017, issue 2
Vinod Prabhu, Venugopal Vinod Prabhu
Targeting the Overexpressed YY1 in Cancer Inhibits EMT and Metastasis
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 1-2
Anne Arah Cho, Benjamin Bonavida